Amarin Corp Plc (AMRN)

[ziploc_1]

The Brave study is involved in Vascepa's ability to delay the onset or reduce the incidence of ALZ in cognitively healthy indivduals....QUOTE

"The goal of this study is to evaluate the efficacy of a purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA) called icosapent ethyl (IPE), on improving brain blood flow, spinal fluid markers of AD pathology, and cognitive performance in middle-aged, cognitively-healthy Veterans with increased risk of AD. If IPE delays the onset of AD by even 5 years, the incidence of AD would be reduced by 50% in this population and could have a profound effect on Veteran quality of life and healthcare costs."

Most previous studies have focused on whether reduction in already established amyloid plaques in the brain can improve ALZ once it is present...and they have failed....This study seems to have a greater chance of success since the anti-inflammatory effects of Vascepa should be helpful in delaying or reducing ALZ.